For over 20 years, Cancer Research for the Ozarks (CRO) has provided NCI-approved clinical trials to the rural communities of Southwestern Missouri and surrounding areas. Through the visionary leadership of physicians Wendall Goodwin, MD and Robert L. Carolla, MD, patients who otherwise would not have access to clinical trials can elect to participate through the Community Clinical Oncology Program. From its inception, CRO has had the support of the two nationally recognized health care systems, CoxHealth and St. John's Health System in Springfield, Missouri. With the later addition of two Joplin affiliates, CRO now provides more than 95 percent of cancer care resources in the area including a physician network of oncologists, radiation oncologists, gynecological oncologists, urologists, surgeons, and primary care specialists. CRO supports the CCOP mission of accelerating development of interventions to prevent and treat cancer by increasing accruals to trials. CRO exceeds five percent patient participation with over 200 patients enrolled to treatment and prevention and control trials each of the past five years. CRO's thirty-three physician investigators actively participate in the program increasing awareness of recent developments in treatment, control and prevention and the overall quality of care in the community. CRO has also successfully increased involvement of minorities enrolling a higher percentage than that of the general cancer population.
!: Research is the future of mankind. Cancer Research for the Ozarks offers NCI oncology treatment along with cancer control and prevention trials to Springfield and the surrounding communities. The ultimate goal of participation is to find the cure for cancer.
|Ahmed, Amina; Deng, Wei; Tew, William et al. (2018) Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol 150:300-305|
|Aghajanian, Carol; Filiaci, Virginia; Dizon, Don S et al. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274-281|
|Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231|
|Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585|
|Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8|
|Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7|
|Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62|
|Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8|
|Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64|
|Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8|
Showing the most recent 10 out of 157 publications